StockTipsArenaBeta

BUY Akums Drugs and Pharmaceuticals — ICICI Securities

BUYAkums Drugs and Pharmaceuticals

byICICI SecuritiesHorizon: NA (inferred 1 year)11 Aug 2026via Institutional / Brokerage Research

Entry₹760.95Inferred
Target₹850
Total upside +11.70%
Stop lossNot given
CMP₹765.752d ago
Active+0.63%+11.00%upside left 11 mo left
Follow ICICI Securities for new calls(68% target hit, 1020 closed calls)Get alertsWatch AKUMS for new buy/sell callsGet alertsSee 2 other Long-term calls on AKUMS

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 1:52 am IST
12 supporting4 neutral0 opposing
Supports the BUY call (12)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·4 Sept · 2d ago

Akums Drugs: Citi hikes target to Rs 860, sees 15% upside on CDMO strength

NewsGoogle News·18 Aug · 3w ago

(opens in new tab)

1 other SEBI-registered advisor has an active long-term BUY call on this stock

Advisor consensus · same horizon·18 Aug · 3w ago

Akums Drugs Q1FY27 net profit surges 56%; concall flags API turnaround

NewsGoogle News·13 Aug · 3w ago

(opens in new tab)

Earnings Beat: Akums Drugs and Pharmaceuticals Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

NewsGoogle News·12 Aug · 4w ago

(opens in new tab)
Neutral / worth noting (4)

Un-audited Financial Results for the Quarter ended 30th June, 2026

BSE · Board Meeting·8 Aug · 4w ago

(opens in new tab)

Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·8 Aug · 4w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.